ABBV vs NVDA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and NVIDIA Corporation β fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. Β· Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
NVIDIA Corporation Β· Technology
$182.08
+59.3% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
NVDA has more upside to fair value
(+59.3%).
These are model outputs β not personalized investment advice.
See all research β
Valuation & Fundamentals
| Metric |
ABBV |
NVDA |
| Current Price |
$208.05 |
$182.08 |
| Fair Value Estimate |
$217.50 |
$290.00 |
| Upside to Fair Value |
+4.5%
|
+59.3%
|
| Market Cap |
$367.9B |
$4,425.5B |
| Forward P/E |
14.9x
|
β
|
| EV / EBITDA |
16.7x
|
31.4x
|
| Price / Sales |
6.1x
|
21.0x
|
| Price / FCF |
20.9x
|
46.9x
|
| Revenue Growth YoY |
+8.6%
|
+65.5%
|
| Gross Margin |
83.7%
|
71.1%
|
| Operating Margin |
34.7%
|
60.4%
|
| Return on Equity |
-129.24%
|
76.3%
|
| Dividend Yield |
3.2% |
0.02% |
| FCF Yield |
4.78%
|
2.13%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billiβ¦
NVIDIA is the foundational infrastructure layer of the AI era. Data Center revenue reached $193.7B in FY2026, up 66% YoY, powered by insatiable demand for Blackwell B200 GPUs across hyperscalers and sovereign AI programs. The company generates $96.7B in annual free cash flow with 71% gross margins and 56% net margins, making it the most profitable semiconductor business in history. At P/E 37.7x vβ¦
Accumulation Zones
| Metric |
ABBV |
NVDA |
| Zone Low |
$163.13 |
$218.00 |
| Zone High |
$184.88 |
$250.00 |
| In Buy Zone? |
No
|
Yes
|